Since such a short term improvement of immune disorders is extremely difficult to achieve, I venture to assume with all reserve a positive effect of the GKL-03
Past News ReleasesRSS
Gainesville, GA (PRWEB) March 2, 2009
Mannheim, Germany -- A new preparation highly beneficial in patients with ailments from common skin disorders to hepatitis or HIV, is now available in the US without a prescription. Oral intake of the GKL03 synthetic peptides induces modulation and regulation of the immune system. GKL03 (Thymrevit) is a demonstrably potent immmunomodulator effective in the short term.
This preparation was first used in 2004 on tumor patients whose immune system was significantly weakened by chemotherapy or radiotherapy which had been carried out or recently administered. All subjects felt significantly better in several chemotherapy phases each time GKL-03 was taken, and also had better excersise tolerance in endurance test. Since 2004, ongoing clinical trials conducted in Germany, has shown GKL-03 to be adventageous in those with tumourigenic disease, cancer or immuno deficiencies. There are unambiguous findings indicating GKL-03 can protect the body from opportunistic infections where the body has been damaged from pre-existing conditions such as chemotherapy, x-rays, or bacterial, fungal or latent viral infections. "Since such a short term improvement of immune disorders is extremely difficult to achieve, I venture to assume with all reserve a positive effect of the GKL-03" --- Dr. Med Knut Briken, Oncology/Immunobiological Cancer Aftercare, Berlin Germany.
Klett-Loch GmbH, a medium size company, located in Mannheim Germany is a top leader in research and development against immune system disorders for over 25 years. Biotechne Complex, Inc. (http://www.biotechne.com) located in Georgia is designated the North American representative since 1995 assisting in continued support and informational programs.